Literature DB >> 17943851

Copper containing, framed intra-uterine devices for contraception.

R Kulier1, P A O'Brien, F M Helmerhorst, M Usher-Patel, C D'Arcangues.   

Abstract

BACKGROUND: Intrauterine devices (IUD) are safe and effective methods of long term reversible contraception. The design, and copper content as well as placement of the copper on IUDs could affect their effectiveness and side-effect profile.
OBJECTIVES: We compared different copper IUDs for their effectiveness and side effects. SEARCH STRATEGY: Multiple electronic databases were searched with appropriate key words and names of the IUDs known to be in the market. We searched the reference lists of papers identified and contacted trialists when possible. There was no language restriction. SELECTION CRITERIA: Randomised controlled trials comparing different IUDs were considered. Trials needed to report on clinical outcomes. DATA COLLECTION AND ANALYSIS: Data on outcomes and trial characteristics were extracted in duplicate and independently by two reviewers. Meta-analysis results are expressed as rate difference (RD) using a fixed-effects model with 95% confidence interval (CI). In the presence of significant heterogeneity a random-effects model was applied. MAIN
RESULTS: We included 35 trials, resulting in 18 comparisons of 10 different IUDs in approximately 48,000 women. TCu380A was more effective in preventing pregnancy than MLCu375 (RD 1.70%, 95% CI 0.07% to 2.95% after 4 years of use). TCu380A was also more effective than MLCu250, TCu220 and TCu200. There tended to be fewer pregnancies with TCu380S compared to TCu380A after the first year of use, a difference which was statistically significant in the fourth year (RD -1.62%, 95% CI -3.00% to -0.24%). This occurred despite more expulsions with TCu380S (RD 3.50%, 95% CI 0.36% to 6.63% at 4 years). MLCu375 was no more effective than TCu220 at 1 year of use, or MLCu250 and NovaT up to 3 years. Compared to TCu380A or TCu380S, none of the IUDs showed any benefits in terms of bleeding or pain, or any of the other reasons for early discontinuation. None of the trials that reported events at insertion found one IUD easier to insert than another or caused less pain at insertion. There is no evidence that uterine perforation rates vary by type of device. There are minimal randomised data on IUD use in nulliparous women. AUTHORS'
CONCLUSIONS: TCu380A or TCu380S appear to be more effective than other IUDs. No IUD showed consistently lower removal rates for bleeding and pain in comparison to other IUDs. There is no evidence that any particular framed copper device is better suited to women who have not had children.

Entities:  

Mesh:

Year:  2007        PMID: 17943851     DOI: 10.1002/14651858.CD005347.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

1.  Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial.

Authors:  Othman Kakaire; Josaphat Kayogoza Byamugisha; Nazarius Mbona Tumwesigye; Kristina Gemzell-Danielsson
Journal:  Hum Reprod       Date:  2015-05-15       Impact factor: 6.918

2.  Immediate postabortion intrauterine device insertion: continuation and satisfaction.

Authors:  Colleen McNicholas; Taylor Hotchkiss; Tessa Madden; Qiuhong Zhao; Jenifer Allsworth; Jeffrey F Peipert
Journal:  Womens Health Issues       Date:  2012 Jul-Aug

3.  The impact of an IUD and implant intervention on dual method use among young women: Results from a cluster randomized trial.

Authors:  Alison M El Ayadi; Corinne H Rocca; Julia E Kohn; Denisse Velazquez; Maya Blum; Sara J Newmann; Cynthia C Harper
Journal:  Prev Med       Date:  2016-10-20       Impact factor: 4.018

4.  Clinical Outcome of Postplacental Copper T 380A Insertion in Women Delivering by Caesarean Section.

Authors:  Sunita Singal; Rekha Bharti; Rupali Dewan; Anjali Dabral; Achla Batra; Manjula Sharma; Pratima Mittal
Journal:  J Clin Diagn Res       Date:  2014-09-20

5.  Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial.

Authors:  David Hubacher; Courtney A Schreiber; David K Turok; Jeffrey T Jensen; Mitchell D Creinin; Kavita Nanda; Katharine O'Connell White; Ila Dayananda; Stephanie B Teal; Pai-Lien Chen; Beatrice A Chen; Alisa B Goldberg; Jennifer L Kerns; Clint Dart; Anita L Nelson; Michael A Thomas; David F Archer; Jill E Brown; Paula M Castaño; Anne E Burke; Bliss Kaneshiro; Diana L Blithe
Journal:  EClinicalMedicine       Date:  2022-07-16

6.  Intrauterine pregnancy with copper intrauterine contraceptive device in situ: A case report from Nepal.

Authors:  Abilasha Rana; Amit Shrestha; Anil Regmi; Shreyashi Aryal; Pragya Karki; Rewant Singh
Journal:  Ann Med Surg (Lond)       Date:  2022-09-25

7.  Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device.

Authors:  Bliss Kaneshiro; Tod Aeby
Journal:  Int J Womens Health       Date:  2010-08-09

8.  Importance of Serum Copper and Vascular Endothelial Growth Factor (VEGF-A) Levels in Postmenopausal Bleeding.

Authors:  Afshan Rafi; Ramakrishna Devaki; K Sabitha; Shruti Mohanty; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2012-07-28

9.  Cervical lidocaine for IUD insertional pain: a randomized controlled trial.

Authors:  Colleen P McNicholas; Tessa Madden; Qiuhong Zhao; Gina Secura; Jenifer E Allsworth; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2012-09-20       Impact factor: 8.661

10.  Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).

Authors:  G Justus Hofmeyr; Charles S Morrison; Jared M Baeten; Tsungai Chipato; Deborah Donnell; Peter Gichangi; Nelly Mugo; Kavita Nanda; Helen Rees; Petrus Steyn; Douglas Taylor
Journal:  Gates Open Res       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.